XML 30 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Stockholder's Equity
3 Months Ended
Mar. 27, 2021
Equity [Abstract]  
Stockholder's Equity Stockholders' Equity
An analysis of stockholders’ equity is shown below (share amounts not in thousands):
Common StockAdditional Paid in CapitalRetained
Earnings
Accumulated Other Comprehensive LossTotal Stockholders’
 Equity
SharesPar Value
For the three months ended March 27, 2021
Balance, January 1, 202163,359,839 $633 $405,161 $422,928 $(133,635)$695,087 
Net income (loss)— — — (27,027)— (27,027)
Other comprehensive income (loss), net of tax
— — — — (7,234)(7,234)
Issuance of common stock under incentive stock plans
369,713 (4)— — — 
Stock-based compensation — — (653)— — (653)
Repurchase of common shares (a)(132,196)(1)(1,418)— — (1,419)
Balance, March 27, 202163,597,356 $636 $403,086 $395,901 $(140,869)$658,754 
For the three months ended March 28, 2020
Balance, January 1, 202063,136,129 $632 $399,020 $422,373 $(139,227)$682,798 
Net income (loss)— — — (24,127)— (24,127)
Other comprehensive income (loss), net of tax
— — — — (20,558)(20,558)
Issuance of common stock under incentive stock plans
290,689 (3)— — — 
Stock-based compensation— — 1,943 — — 1,943 
Repurchase of common shares (a)(179,951)(3)(435)— — (438)
Balance, March 28, 202063,246,867 $632 $400,525 $398,246 $(159,785)$639,618 
(a) Repurchased to satisfy the tax withholding requirements related to the issuance of stock under the Rayonier Advanced Materials Incentive Stock Plan.
Common Stock Buyback
On January 29, 2018, the Board of Directors authorized a share buyback program pursuant to which the Company may, from time to time, purchase shares of its common stock with an aggregate purchase price of up to $100 million. During the three months ended March 27, 2021 and March 28, 2020, the Company did not repurchase any common shares under this buyback program. As of March 27, 2021, there was approximately $60 million of share repurchase authorization remaining under the program. The Company does not expect to utilize any further authorization in the near future.